Aptar Pharma signs development and license agreement with BD to bring a novel auto-injector to market
![](/46/pdcnewsitem/04/26/12/aptar.jpg)
Compact device capable of delivering high viscosity drugs including some of the newest biologics.
Aptar Pharma has signed an exclusive development and license agreement with Becton, Dickinson and Company (BD) to jointly develop a novel auto-injector using Aptar Pharma’s high performance, two-step auto-injector technology and prefillable syringes from BD.
Auto-injectors are designed to be used safely and conveniently by patients for self-injection in a non-medical environment, such as the home or office.
Aptar Pharma has utilized feedback obtained from its market research involving patients and healthcare professionals to create and optimize a compact device capable of delivering high viscosity drugs including some of the newest biologics.
The auto-injector technology was specifically designed around the BD Neopak 1 mL long glass prefillable syringe or the BD Hypak for Biotech 1 mL long glass prefillable syringe to optimize system robustness and performance.
Under the agreement, BD, a leading global medical technology company with a broad portfolio of innovative drug delivery systems, and Aptar Pharma will jointly develop Aptar Pharma’s auto-injector technology platform using BD’s expertise in prefillable syringes and self-injection technologies combined with Aptar Pharma’s innovation and quality-by-design expertise.
This unique two-step auto-injector will be exclusively commercialized by BD as a part of their portfolio of auto-injectors.
“We are pleased to be extending our relationship with BD from pharmaceutical elastomer components supplier to now also include joint development of an auto-injector system. The key advantages of this platform hinge on the ease of use, ergonomic shape, improved feedback indicators, and the ability to handle viscous drug formulations,” said Salim Haffar, President of Aptar Pharma.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance